Drug Profile
Ceralasertib - AstraZeneca/University of Pennsylvania
Alternative Names: AZD 6738Latest Information Update: 17 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca; University of Pennsylvania
- Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
- Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Cholangiocarcinoma; Gastric cancer; Gynaecological cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Phase I/II Chronic lymphocytic leukaemia
- Preclinical Diffuse large B cell lymphoma; Type 1 diabetes mellitus
- No development reported B-cell lymphoma; Chronic myelomonocytic leukaemia; Head and neck cancer; Lymphoid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Discontinued Haematological malignancies
Most Recent Events
- 08 Jan 2024 NHS Greater Glasgow, Clyde Health Board and AstraZeneca terminates a Phase-II clinical trials in Pancreatic cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, In adolescents, In adults, In the elderly) in United Kingdom (PO)due to lack of staff/facilities/resources as of January 2024 (EudraCT2018-003971-37) (ISRCTN16004234)
- 25 Oct 2023 Samsung Medical Center in collaboration with AstraZeneca completes a phase II SUKSES-N4 trial for Small cell lung cancer (Combination therapy, Second line therapy or greater) in South Korea (IV) (NCT04361825)
- 20 Oct 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in South Korea, USA (PO) (NCT02264678)